Combined therapy of human interferon (HI) and secretory immunoglobulin (S-IgA) in the treatment of human herpetic keratitis.
The topical action of a combined therapy of human interferon (3000 U/ml) and secretory immunoglobulin IgA (1,5 mg/ml) was studied in 56 patients with herpetic keratitis. The pain and photophobia disappeared within 48 h after the beginning of treatment and a marked reduction of the corneal lesion during the first week of treatment was observed in all the patients. The therapy was effective, with complete healing of the lesion in 94.8% of cases; 72.2% of them healed in less than 15 days. The highest frequency of healing was between 5 and 10 days, and the rest up to 30 days. Humoral, immunological and delayed hypersensitivity studies were carried out in 36 patients.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D006801:Humans; D007070:Immunoglobulin A / Q000627:therapeutic use*; D007071:Immunoglobulin A, Secretory / Q000627:therapeutic use*; D007223:Infant; D007372:Interferons / Q000627:therapeutic use*; D007635:Keratitis, Dendritic / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D012882:Skin Tests; D013997:Time Factors
D007070:Immunoglobulin A; D007071:Immunoglobulin A, Secretory; D007372:Interferons